Treatment outcomes in NTM-PD in a high TB burden context
BACKGROUND: Non-tuberculous mycobacterial (NTM) pulmonary disease (PD) is a significant concern in China, compounding the existing burden of TB. This review aims to summarise the treatment outcomes for NTM-PD in China. METHODS: We reviewed the evidence on NTM-PD, including treatment regimens and cli...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
International Union Against Tuberculosis and Lung Disease (The Union)
2024-12-01
|
| Series: | IJTLD Open |
| Subjects: | |
| Online Access: | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000012/art00004 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590566964068352 |
|---|---|
| author | S. Kang J.E. Schmidt I. Chen S. Tiberi |
| author_facet | S. Kang J.E. Schmidt I. Chen S. Tiberi |
| author_sort | S. Kang |
| collection | DOAJ |
| description | BACKGROUND: Non-tuberculous mycobacterial (NTM) pulmonary disease (PD) is a significant concern in China, compounding the existing burden of TB. This review aims to summarise the treatment outcomes for NTM-PD in China. METHODS: We reviewed the evidence on NTM-PD, including treatment regimens and clinical outcomes, from 17 studies identified through screening of three Chinese biomedical databases. RESULTS: Antimicrobial treatment showed a microbiological cure rate ranging from 17.2% to 60.0% in studies with ≥50 NTM-PD patients, with lower rates observed among older and malnourished patients. The Mycobacterium chelonae abscessus group (MC-AG) and Mycobacterium avium-intracellulare complex (MAC) were the most prevalent NTM species in China. Higher microbiological cure rates were seen in MAC PD compared with MC-AG PD. The addition of cefoxitin and linezolid improved culture conversion rates in MC-AG-infected patients. One study ( n = 24) demonstrated that resecting lesions and chemotherapy led to more favourable clinical outcomes. CONCLUSION: Treatment regimens recommended in Chinese guidelines yielded poor-to-moderate outcomes for NTM-PD in China, highlighting the need for further research into alternative antimicrobial treatments to improve efficacy. |
| format | Article |
| id | doaj-art-d432cdde736c4bb9bc923a4cd654373f |
| institution | Kabale University |
| issn | 3005-7590 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | International Union Against Tuberculosis and Lung Disease (The Union) |
| record_format | Article |
| series | IJTLD Open |
| spelling | doaj-art-d432cdde736c4bb9bc923a4cd654373f2025-01-23T13:29:23ZengInternational Union Against Tuberculosis and Lung Disease (The Union)IJTLD Open3005-75902024-12-0111254755510.5588/ijtldopen.24.04134Treatment outcomes in NTM-PD in a high TB burden contextS. Kang0J.E. Schmidt1I. Chen2S. Tiberi3GSK, Beijing, China;GSK, Siena, Italy;GSK, Shanghai, China;GSK, Brentford, UK;BACKGROUND: Non-tuberculous mycobacterial (NTM) pulmonary disease (PD) is a significant concern in China, compounding the existing burden of TB. This review aims to summarise the treatment outcomes for NTM-PD in China. METHODS: We reviewed the evidence on NTM-PD, including treatment regimens and clinical outcomes, from 17 studies identified through screening of three Chinese biomedical databases. RESULTS: Antimicrobial treatment showed a microbiological cure rate ranging from 17.2% to 60.0% in studies with ≥50 NTM-PD patients, with lower rates observed among older and malnourished patients. The Mycobacterium chelonae abscessus group (MC-AG) and Mycobacterium avium-intracellulare complex (MAC) were the most prevalent NTM species in China. Higher microbiological cure rates were seen in MAC PD compared with MC-AG PD. The addition of cefoxitin and linezolid improved culture conversion rates in MC-AG-infected patients. One study ( n = 24) demonstrated that resecting lesions and chemotherapy led to more favourable clinical outcomes. CONCLUSION: Treatment regimens recommended in Chinese guidelines yielded poor-to-moderate outcomes for NTM-PD in China, highlighting the need for further research into alternative antimicrobial treatments to improve efficacy.https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000012/art00004antimicrobial treatmentchinaclinical outcomesnon-tuberculous mycobacterial pulmonary diseasenon-tuberculous mycobacteria |
| spellingShingle | S. Kang J.E. Schmidt I. Chen S. Tiberi Treatment outcomes in NTM-PD in a high TB burden context IJTLD Open antimicrobial treatment china clinical outcomes non-tuberculous mycobacterial pulmonary disease non-tuberculous mycobacteria |
| title | Treatment outcomes in NTM-PD in a high TB burden context |
| title_full | Treatment outcomes in NTM-PD in a high TB burden context |
| title_fullStr | Treatment outcomes in NTM-PD in a high TB burden context |
| title_full_unstemmed | Treatment outcomes in NTM-PD in a high TB burden context |
| title_short | Treatment outcomes in NTM-PD in a high TB burden context |
| title_sort | treatment outcomes in ntm pd in a high tb burden context |
| topic | antimicrobial treatment china clinical outcomes non-tuberculous mycobacterial pulmonary disease non-tuberculous mycobacteria |
| url | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000012/art00004 |
| work_keys_str_mv | AT skang treatmentoutcomesinntmpdinahightbburdencontext AT jeschmidt treatmentoutcomesinntmpdinahightbburdencontext AT ichen treatmentoutcomesinntmpdinahightbburdencontext AT stiberi treatmentoutcomesinntmpdinahightbburdencontext |